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Abstract — Numerous epidemiologic studies showed an inverse correlation 
between dietary flavonoid consumption and cardiovascular risk, but the exact 
mechanisms are still largely unknown. Flavonoids exhibit hormetic properties, 
where low concentrations activate adaptive cellular stress response pathways 
and thus lead towards cytoprotection, whereas high concentrations are 
cytotoxic. However, the limited bioavailability of dietary flavonoids doubts the 
relevance of effective flavonoid intracellular concentrations to induce bioactivity 
in endothelial cells. Therefore, translocation of flavonoids through the cell plasma 
membrane must occur via specific transporter proteins. Hereby, we describe the 
involvement of the membrane transporter bilitranslocase (TC #2.A.65.1.1) as 
the key underlying molecular mechanism for membrane transport, which might 
help resolve the enigma of flavonoids bioactivity.
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1 FLAVONOIDS AND CARDIOVASCULAR hEALTh
Numerous epidemiological studies have shown that regular intake of flavonoids is associated with an improved cardiovascular prognosis [1,2]. In the setting 
of primary prevention, individuals with the highest flavonoid intake have modestly 
reduced risks for developing cardiovascular disease [3-5]. In addition, flavonoid intake 
benefits individuals with established cardiovascular disease. This can be seen from 
clinical signs like lowered blood pressure [6-8], improved endothelial function [9-11], 
inhibited platelet aggregation [7,12-14], decreased low density lipoprotein oxidation 
[15,16], and reduced inflammatory responses [17-19]. 
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To promote the idea of healthy diet, it is now clear that the medical researcher must 
put big efforts in providing concise explanations how the potential beneficial effects 
of flavonoids can arise. Scientists have a responsibility to investigate this issue, 
and provide the general public evidence-based guidelines on a healthy diet. Even 
more, researchers must try to isolate the therapeutic lead molecules, and chemically 
improve them, to obtain new potential drugs for treating specific pathophysiological 
conditions. So far, exact mechanisms of how flavonoids act are still largely obscure, 
and thus represent a big challenge for research, whether in academia or in the 
pharmaceutical and the nutraceutical industry. 
2 PhARMACOKINETIC CONCERNS RELATED TO ThE FLAVONOIDS    
 PhARMACODyNAMICS
The biggest pharmacological concern of dietary flavonoids can be attributed to their limited bioavailability, which results in very low plasma concentrations 
(0.1-1 μM) [20]. This questions whether intra-cellular concentrations attain levels 
that are of any relevance to the endothelial function [21]. In fact, it is not clear if 
flavonoids interact with any endothelial plasma membrane receptors and thus act by 
triggering an intracellular signal transduction cascade, or they penetrate into the cells 
and, consequently, bind to intracellular molecular targets. In the latter hypothetic 
pathway, translocation of flavonoids through the cell plasma membrane must occur 
via specific transport proteins [22].
On the other hand, high plasma flavonoid concentrations might have deleterious 
systemic effects, as it is suggested by some of theirs on the cardiovascular system 
[23]. Though still isolated, these observations warn against the potential alternative 
routes of administration, i.e. parenteral, which would avoid the low absorption and 
first-pass metabolism issues, or utilization of the enhanced absorption delivery 
systems.
It is widely accepted that flavonoids are good antioxidants when chemically tested 
in in vitro non-biological systems, but little emphasis is put on the fact that most of 
those studies showed effects in the supra-physiological concentration ranges, many 
magnitudes of order higher than reported in vivo. Thus, there is now a more plausible 
hypothesis that the in vivo beneficial effects of these phytochemicals are unlikely 
to be explained just by their per se antioxidant capability. Flavonoids may exhibit 
hormetic properties, by acting as `low-dose stressors’ that may prepare cells to resist 
more severe oxidative stress, while high concentrations are cytotoxic [24]. In this 
biphasic manner, low concentrations of flavonoids induce cardiovascular protection, 
while high concentrations are cardiotoxic [23]. 
This is meaningful since low and transient concentrations of flavonoids in the plasma 
contribute little per se to the overall plasma antioxidant status, when compared to 
the relatively higher concentrations of other antioxidants in plasma, e.g. vitamin C, 
uric acid, bilirubin, etc. Taken altogether, the diverse chemical structures of flavonoids 
exhibit molecular mimicry with many mammalian endogenous molecules, thereby 
leading to manifold biological effects, i.e. altering intracellular signaling pathways and 
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enzyme activities. Compared to the specific activity of other plant-related chemicals, 
for example morphine’s high affinity targeting of the opiate receptors, flavonoids 
have been always on the borderline between pharmaceuticals and xenobiotics. Since 
they don’t have any specific cellular targets, as indirectly confirmed by all flavonoids-
related studies with only partial inhibition and/or activation of numerous examined 
molecular targets, they should, in our opinion, fall in the category of xenobiotics. 
From an evolutionary perspective, flavonoids are primarily produced by plants to 
prevent insects and other animals to eat plants, and this again speaks in favor that 
the observed bioactivity of flavonoids from animal and human studies is actually 
resulting from the activation of adaptive cellular stress response pathways [25,26]. 
On the other hand, we must also consider the plausibility that there do exist some 
conservative proteins in nearly all animals, who eat the flavonoid-rich plants, and 
there are also similar proteins found in both the plant and animal kingdoms. Many 
of these are still largely unknown in humans, but can profoundly influence both the 
pharmacokinetic or pharmacodynamics properties of flavonoids.
3 BILITRANSLOCASE TRANSPORTS FLAVONOIDS INTO ThE CELLS 
There is a big question in the science: how can flavonoids enter into the cells? A potentially involved carrier is bilitranslocase (TC #2.A.65.1.1) [27], a bilirubin-
specific membrane protein that is also responsible for ATP-independent transport 
of flavonoids across cell membranes in various rat organs, e.g. on the epithelium 
of liver, gastrointestinal system, kidney, brain, lungs, etc., and also on the vascular 
endothelium [28]. Even though the investigation has not yet covered all mammalian 
tissues or other species, data already suggest that bilitranslocase might be a 
ubiquitous membrane protein, therefore playing a major role in biology.
Based on extensive transport activity assays performed on a battery of flavonoids 
subclasses, bilitranslocase can be considered as an anthocyanin-selective transporter, 
since other flavonoids are not effective ligands [27]. This selective interaction can be 
explained in terms of molecular mimicry between bilirubin and anthocyanins, as well 
as by specific structural characteristics of anthocyanins, such as the planar system 
of conjugated aromatic rings and pH-dependent tautomerism, which by protonation 
converts the quinoidal form into the phenolic form [29].
Bilitranslocase is expressed both in the vascular system, on the endothelium and 
vascular smooth muscle cells [28], and also in the cardiac system, on the endocardium 
and cardiomyocytes (data not yet published). This presence enables to understand 
some of the cardiovascular effects of flavonoids, which are summarized in the Table 1. 
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1. DIMINUTION OF OXIDATIVE STRESS
Direct scavenging of free radicals (antioxidant action in 
the narrow sense of the word)
Metal interaction (iron and/or copper chelation)
Inhibition of ROS producing enzymes, in particular xan-
thine oxidase, NADPH oxidase and lipoxygenases
Stimulation of endogenous antioxidant defense mecha-
nisms, increase in expression of eNOS, intracellular 
glutathione
2. DECREASE IN ThE EXPRESSION OF 
INFLAMMATORy SIGNALING MOLECULES
Inhibition of iNOS expression (endothelium)
Inhibition of COX-2 expression  (endothelium)
Inhibition of leukocyte activation
3. INhIBITION OF PLATELET AGGREGATION
Increase in platelet NO production
Decrease in platelet production of superoxide anion
4. DIRECT VASODILATORy ACTION
Activation of eNOS signaling pathway in the endothe-
lium, leading to release of NO
Activation of EDHF-mediated vasorelaxation in the 
endothelium
Direct effects on ion channels
Inhibition of cyclic adenosine monophosphate-
dependent phosphodiesterase
5. OThER CARDIOVASCULAR ACTIVITIES
Isoflavones improve endothelial function through an 
effect on α estrogen receptor
Positive/negative inotropic effects
Activation of PPARy
Table 1. List of potential protective effects of flavonoids in the cardiovascular system. Adapted from [30].
4 ROLE OF BILITRANSLOCASE IN ThE CARDIOVASCULAR SySTEM
We have made a significant progress in our understanding of the functional role of the bilitranslocase protein in the cardiovascular system. Original approach 
towards studying the protein function was based upon the inhibition of the 
bilitranslocase activity by using anti-sequence bilitranslocase antibodies. They target 
distinct extracellular epitopes of the carrier, and thereby inhibit the transport of the 
substrates into the cytoplasm. 
The data obtained from our experiments suggest that even low concentrations (in 
nM range) of flavonoids, which are comparable to post-absorption plasma levels, are 
rapidly (<1min) taken up into the endothelium via bilitranslocase (Ziberna, FRBM, 
under review). This rapid uptake into endothelial cells can be explained only by the 
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involvement of specific membrane transporters that catalyze the passage of polar 
substances, such as flavonoids, through the phospholipid bilayer.
Furthermore, bilitranslocase represents a key step in the flavonoids-induced 
endothelial cell-signaling cascade leading to the activation of intracellular PI3- 
kinase/Akt/eNOS pathway (Ziberna, not yet published), as schematically shown on 
Figure 1. Accordingly, bilitranslocase mediates the vasorelaxation responses induced 
by flavonoids [31].
Figure 1. Scheme indicating that flavonoids are potent inducers of the endothelial formation of NO and 
EDHF with their corresponding different intracellular signaling pathways. BTL – bilitranslocase, EDHF 
– endothelium derived hyperpolarizing factor, NO – nitric oxide, eNOS – endothelial NO synthase, PI3K 
– phosphatidyl-inositol 3-kinase, PDK1 – posphoinositide-dependent kinase 1, ROS – reactive oxygen 
species, sGC – soluble guanylyl cyclase. Adapted from [30].
In the cardiac system, we introduced an innovative approach of retrograde 
coronary perfusion with the bolus of the bilitranslocase antibodies. Thus, specific 
immunocomplexes were formed on the surface of the coronary endothelium and in a 
lesser extent, if at all, on the endocardium of the left atrium and ventricle. Importantly, 
unbound immunoglobulins were removed by continuous perfusion. We found that 
bilitranslocase mediates the cardioprotective activity of flavonoids in ischemia-
reperfusion model of the isolated heart, as observed by measuring coronary flow, 
cardiomyocyte lysis and duration of arrhythmias (Ziberna, FRBM, under review). 
5 INTERPLAy BETWEEN FLAVONOIDS AND BILIRUBIN
Given the mutual metabolic interference between flavonoids and bilirubin, it can be speculated that the transient increase in the antioxidant capacity of endothelium 
following ingestion of flavonoids [32] might be, in part, ascribed to a transient and 
reversible decrease of bilirubin clearance by the endothelial cells. Furthermore, it can 
be speculated that flavonoids occupy the activity of bilitranslocase, thus decreasing 
the endothelial efflux of intracellular (endogenous) bilirubin, which is constantly 
produced by heme oxygenase-1 and biliverdin reductase. Since bilirubin is a strong 
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endogenous antioxidant, it can be speculated that even a very small increase in basal 
levels of free bilirubin can provide significant antioxidant protection of endothelium 
[33]. In fact, patients with Gilbert’s syndrome, a hereditary condition characterized 
by slightly elevated bilirubin plasma levels and occasional mild and intermittent 
jaundice, show a decreased risk of cardiovascular diseases in comparison to normo-
bilirubinemic populations [34,35].
6 CARDIOVASCULAR RESEARCh ON ThE BILITRANSLOCASE WIThIN    
 TRANS2CARE PROjECT
In the framework of TRANS2CARE project, we will continue to further elaborate our cardiovascular research on the role of bilitranslocase, jointly with our project 
partners:
•	 collaboration with PP1 – Chemical Institute of Ljubljana: in the field of computational 
modeling and chemometrics (QSAR); 
•	 collaboration with PP3 – University of Nova Gorica: studying the metabolism and 
fast-uptake of flavonoids and bilirubin into endothelial cells; 
•	 collaboration with PP10 – Blood Transfusion Center of Slovenia: development 
of novel monoclonal antibodies against bilitranslocase, which are crucial for 
our platform of functional studies, as well as having the potential to be used as 
biomarkers; 
Furthermore, we will also expand our network, in accordance with WP7 - Enlargement 
and consolidation of the network, towards the research groups outside the network:
•	 collaboration with University of Trieste, Department of Materials and Natural 
Resources, CENMAT, contact person Alois Bonifacio: employing SERS Raman 
spectroscopy to detect low concentration of bilirubin in the extracellular and 
intracellular environment;
•	 collaboration with IASMA Research and Innovation Center, Food Quality and 
Nutrition Area, San Michele all’Adige, contact person Fulvio Mattivi: metabolomics 
experiments on the effects of flavonoids in cardiovascular tissues.
7 CONCLUSION
The knowledge presented is important for the better understanding of diet-based preventive medicine, which is an affordable and efficient way of improving 
worldwide health. Academic world must, therefore, provide the rationale for specific 
dietary guidelines about including flavonoids-rich food in the diet. And the people 
will have no hesitation to make excellent life choices in the direction of achieving 
significant health benefits.
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